ADMA Biologics Inc $ADMA Position Boosted by Fox Run Management L.L.C.

Key Points

• Fox Run Management L.L.C. increased its holdings in ADMA Biologics Inc by 79.5% in the first quarter, resulting in a total investment valued at $681,000.
• Institutional investment in ADMA Biologics is significant, with hedge funds owning approximately 75.68% of the stock, indicating strong market confidence.
• ADMA Biologics reported a net margin of 44.06% for the latest quarter, with a revenue increase of 13.8% year-over-year, showcasing its financial growth.

Fox Run Management L.L.C. grew its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 79.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,306 shares of the biotechnology company's stock after purchasing an additional 15,189 shares during the period. Fox Run Management L.L.C.'s holdings in ADMA Biologics were worth $681,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ADMA. Invesco Ltd. lifted its stake in shares of ADMA Biologics by 13.9% during the first quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock valued at $255,279,000 after buying an additional 1,570,649 shares during the period. Nuveen LLC purchased a new position in shares of ADMA Biologics during the 1st quarter worth $93,543,000. Dimensional Fund Advisors LP boosted its holdings in shares of ADMA Biologics by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after purchasing an additional 643,661 shares during the last quarter. Oberweis Asset Management Inc. boosted its holdings in shares of ADMA Biologics by 15.0% during the fourth quarter. Oberweis Asset Management Inc. now owns 3,342,560 shares of the biotechnology company's stock worth $57,325,000 after purchasing an additional 435,480 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of ADMA Biologics by 7.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,048,946 shares of the biotechnology company's stock valued at $59,211,000 after purchasing an additional 207,097 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

Insider Buying and Selling

In related news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the transaction, the director owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director owned 87,330 shares in the company, valued at $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 455,621 shares of company stock worth $9,461,633. 3.50% of the stock is currently owned by corporate insiders.

ADMA Biologics Stock Down 1.0%

Shares of NASDAQ ADMA traded down $0.1750 on Thursday, hitting $17.1250. The company had a trading volume of 1,346,869 shares, compared to its average volume of 3,128,751. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The firm has a market capitalization of $4.09 billion, a P/E ratio of 19.91 and a beta of 0.38. The business has a 50 day moving average of $18.06 and a two-hundred day moving average of $18.86.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.ADMA Biologics's revenue for the quarter was up 13.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.13 EPS. As a group, equities research analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ADMA shares. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial upped their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.